Lunit Launches Breast Cancer Screening AI Solution 'Insight DBT' in Europe

Presentation of DBT Research Abstract at the European Society of Radiology

[Asia Economy Reporter Myunghwan Lee] Medical artificial intelligence (AI) company Lunit announced on the 23rd that it will launch its 3D breast tomosynthesis AI image analysis solution, 'Lunit Insight DBT,' in the European market.

Lunit's 3D breast tomosynthesis artificial intelligence (AI) image analysis solution, 'Lunit Insight DBT'.
[Photo by Lunit]

Lunit Insight DBT is a product that analyzes 3D images from breast tomosynthesis (DBT) to assist medical professionals in diagnosing breast cancer. According to Lunit, DBT allows for detailed examination of nodules detected in conventional 2D mammography. Lunit completed the development of Lunit Insight DBT in June last year and obtained export approval from the Ministry of Food and Drug Safety last month. Lunit plans to focus on selling Insight DBT through its recently established European subsidiary, Lunit Europe Holdings.

Additionally, Lunit will participate in the 'European Congress of Radiology 2023 (ECR 2023)' held in Vienna, Austria, from the 1st to the 5th of next month, where it will present four research abstracts on Lunit Insight DBT and the mammography AI image analysis solution 'Lunit Insight MMG.'

The research related to Lunit Insight DBT has been selected for an oral presentation, which is a major research category at this conference. Analyzing breast cancer detection accuracy and performance in 162 women with an average age of 52 using Lunit Insight DBT, the accuracy, sensitivity, and specificity of Lunit Insight DBT were confirmed to be 93.2%, 75%, and 94.7%, respectively.

The second study will present an oral presentation comparing the performance of Lunit Insight MMG with other companies' breast cancer diagnostic solutions. Based on 59,246 mammography data sets taken from BreastScreen Norway between 2009 and 2018, the comparison showed that Lunit Insight MMG demonstrated superior breast cancer detection performance compared to other solutions.

Seobum Seok, CEO of Lunit, said, "In just over three years since starting the development of Lunit Insight DBT, we are launching the product in Europe, where there is high demand for precise breast cancer diagnosis, and by presenting our research results at this ECR, we have once again proven our world-class technology. Since this new product offers a higher level of cancer diagnosis accuracy through 3D image analysis, we will accelerate the expansion of our distribution network through our European subsidiary."

This content was produced with the assistance of AI translation services.